Delivery Order SPE2DB20D2104-SPE2DB25FMWUC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,691.58 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,479.50 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets in quantities of 60 units. This firm fixed-price, competitively awarded contract was issued on August 1, 2025, with an ultimate completion date of August 4, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $26,193.92 by the Defense Logistics Agency on August 7, 2025, for the supply of Ibsrela 50 mg tablets in quantities of 60 units. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ibsrela 50 mg tablets (60-count unit) valued at $1,926.04. This firm fixed-price contract, which reaches completion on August 6, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The delivery order carries no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ibsrela 50 mg tablets (60 count) under a firm fixed-price contract valued at $4,847.75. This non-set-aside award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle that runs through December 2026 and supports pharmaceutical procurement for military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ibsrela 50 mg tablets (60 count) under a firm fixed-price contract valued at $14,991.13. This non-set-aside delivery order was competitively awarded and is set to complete by August 6, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ibsrela 50 mg tablets (60 count) with a ceiling value of $10,513.99. This firm fixed-price delivery order, which is not set-aside for small business or other designated groups, is scheduled for completion by August 1, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for pharmaceutical supplies totaling $3,425.94, with completion scheduled for August 18, 2025. This non-set-aside, competitively awarded contract covers the supply of Ibsrela 50 mg tablets (60-count units) to be delivered to the contractor's facility in Conshohocken, Pennsylvania. The award employs firm fixed pricing under a delivery order contract type, reflecting the standardized procurement approach...
- The Defense Logistics Agency awarded a delivery order valued at $2,898.52 to AmerisourceBergen Drug Corp for IBSRELA 50 MG tablets (60-count units) on August 12, 2025, with an ultimate completion date of August 13, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,266.36 by the Defense Logistics Agency (DLA) on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract, which is not set-aside and competitively awarded, calls for the delivery of Ibsrela 50 mg tablets in quantities of 60 units. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMWUCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,143.48 to AmerisourceBergen Drug Corp for 60 tablets of Ibsrela 50 mg, to be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This firm fixed price delivery order, awarded on July 29, 2025, with an ultimate completion date of July 30, 2025, represents a non-set-aside competitive award and is classified as a child contract under a larger vehicle. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 pharmaceutical prime vendor vehicle running through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen leverages this comprehensive global contract to supply medications and medical supplies supporting military healthcare programs and other government health systems worldwide. The company's extensive portfolio with DLA includes specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 7/29/25 |